Mathew I. Milowsky

457 total citations
22 papers, 324 citations indexed

About

Mathew I. Milowsky is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Mathew I. Milowsky has authored 22 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 8 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Cancer Research. Recurrent topics in Mathew I. Milowsky's work include Prostate Cancer Treatment and Research (8 papers), Renal cell carcinoma treatment (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Mathew I. Milowsky is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Renal cell carcinoma treatment (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Mathew I. Milowsky collaborates with scholars based in United States, Taiwan and Ireland. Mathew I. Milowsky's co-authors include David M. Nanus, Neil H. Bander, Stanley J. Goldsmith, Shankar Vallabhajosula, Lale Kostakoğlu, Angela K. Green, Robert W. Corty, Ethan Basch, Katherine E. Reeder‐Hayes and William A. Wood and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Mathew I. Milowsky

21 papers receiving 316 citations

Peers

Countries citing papers authored by Mathew I. Milowsky

Since Specialization

Citations

This map shows the geographic impact of Mathew I. Milowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathew I. Milowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathew I. Milowsky more than expected).

Fields of papers citing papers by Mathew I. Milowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathew I. Milowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathew I. Milowsky. The network helps show where Mathew I. Milowsky may publish in the future.

Co-authorship network of co-authors of Mathew I. Milowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Mathew I. Milowsky. A scholar is included among the top collaborators of Mathew I. Milowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathew I. Milowsky. Mathew I. Milowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma 2024 ·UNC Libraries ·Li Wang, Weili Lin, Michael Woods, Amir H. Khandani, (unknown), Sheng‐Che Hung, W. Kimryn Rathmell, Samira A. Brooks, (unknown), Mathew I. Milowsky, Dinggang Shen, Eric Wallen, Julia R. Fielding	0
2	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma 2020 ·JCI Insight ·Christopher G. Wood, James E. Ferguson, Joel S. Parker, Dominic T. Moore, Jennifer G. Whisenant, Susan J. Maygarden, Eric Wallen, William Y. Kim, Mathew I. Milowsky, Kathryn E. Beckermann, Nancy B. Davis, Scott M. Haake, José A. Karam, Dante S. Bortone, Benjamin G. Vincent, Thomas Powles, W. Kimryn Rathmell	19
3	Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma 2018 ·Clinical Radiology ·(unknown), Sheng‐Che Hung, W. Kimryn Rathmell, (unknown), Li Wang, Weili Lin, Julia R. Fielding, Amir H. Khandani, Michael Woods, Mathew I. Milowsky, Samira A. Brooks, Eric Wallen, Dinggang Shen	31
4	Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression 2016 ·Clinical Cancer Research ·Samira A. Brooks, Amir H. Khandani, Julia R. Fielding, Weili Lin, (unknown), Yueh Z. Lee, Alexandra Arreola, Mathew I. Milowsky, Eric Wallen, Michael Woods, (unknown), (unknown), Joel S. Parker, David S. Lalush, W. Kimryn Rathmell	19
5	The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data 2015 ·The Oncologist ·Angela K. Green, Katherine E. Reeder‐Hayes, Robert W. Corty, Ethan Basch, Mathew I. Milowsky, Stacie B. Dusetzina, Antonia V. Bennett, William A. Wood	69
6	Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host 2013 ·Annals of Oncology ·David Gallagher, Joseph Vijai, Robert J. Hamilton, Irina Ostrovnaya, Gopa Iyer, Ilana Garcia-Grossman, (unknown), Jennifer A. Przybylo, Shaheen Alanee, Jamie C. Riches, Ashley Marie Regazzi, Mathew I. Milowsky, Kenneth Offit, Dean F. Bajorin	11
7	Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC). 2011 ·Journal of Clinical Oncology ·(unknown), (unknown), Naveed Akhtar, Shom Goel, (unknown), (unknown), Himisha Beltran, Mathew I. Milowsky, Madhu Mazumdar, James R. Wright, David M. Nanus	2
8	A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. 2011 ·Journal of Clinical Oncology ·Mathew I. Milowsky, Gerald Carlson, M. Shi, Gladys Urbanowitz, (unknown), C. Sternberg	7
9	Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC). 2011 ·Journal of Clinical Oncology ·David Gallagher, Joseph Vijai, Robert J. Hamilton, Irina Ostrovnaya, Ilana Garcia-Grossman, Jamie C. Riches, Ashley Marie Regazzi, Jennifer A. Przybylo, Marc Gaudet, Mathew I. Milowsky, Kenneth Offit, Dean F. Bajorin	3
10	Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma. 2011 ·Journal of Clinical Oncology ·Hikmat Al‐Ahmadie, Gopa Iyer, Oscar Lin, Anuradha Gopalan, Samson W. Fine, Satish K. Tickoo, Victor E. Reuter, Dean F. Bajorin, Mathew I. Milowsky, David B. Solit	4
11	Circulating tumor cells in patients with metastatic urothelial cancer 2008 ·Journal of Clinical Oncology ·Mathew I. Milowsky, Nicole Ishill, Jamie C. Riches, Martin Fleisher, A. Trout, Anna Maria Valentini, (unknown), Dean F. Bajorin	1
12	Sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC): Updated phase I results from a phase I/II trial (NCI 6981) 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), Mathew I. Milowsky, (unknown), (unknown), (unknown), Deborah Lehrer, Jason Kaplan, David M. Nanus	2
13	Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC) 2008 ·Journal of Clinical Oncology ·Scott T. Tagawa, Mathew I. Milowsky, M. J. Morris, Shankar Vallabhajosula, Stanley J. Goldsmith, (unknown), Jason Kaplan, Frédérique Berger, Howard I. Scher, Neil H. Bander, David M. Nanus	26
14	Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) 2007 ·Journal of Clinical Oncology ·Neil H. Bander, David M. Nanus, Mathew I. Milowsky, M. J. Morris, (unknown), Shankar Vallabhajosula, Stanley J. Goldsmith	2
15	4519 POSTER Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC) 2007 ·European Journal of Cancer Supplements ·(unknown), Mathew I. Milowsky, Scott R. Gerst, Alexia Iasonos, (unknown), Jamie C. Riches, (unknown)	1
16	Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC) 2006 ·Journal of Clinical Oncology ·Mathew I. Milowsky, Matthew D. Galsky, Daniel J. George, Jesse M. Lewin, (unknown), Tracey Marshall, Michael Chang, David M. Nanus, Iain J. Webb, Howard I. Scher	12
17	Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma (TCC) (1998–2003): A report from the National Cancer Data Base (NCDB) 2006 ·Journal of Clinical Oncology ·(unknown), David M. Nanus, Mathew I. Milowsky, (unknown), Alexandra Stewart, PR Carroll	1
18	Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC) 2006 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Supriya G. Mohile, Gary Shelton, Robert Carr, Joyce Steinberg, (unknown), J Melia, Matthew J. Rieser, David M. Nanus, Mathew I. Milowsky	2
19	Phase 2 trial of ¹⁷⁷Lutetium (¹⁷⁷Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) 2006 ·Journal of Clinical Oncology ·M. J. Morris, Mathew I. Milowsky, Neeta Pandit‐Taskar, Chaitanya Divgi, (unknown), (unknown), Shankar Vallabhajosula, Stanley J. Goldsmith, Howard I. Scher, David M. Nanus	5
20	Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity 2005 ·Clinical Cancer Research ·Shankar Vallabhajosula, Stanley J. Goldsmith, Lale Kostakoğlu, Mathew I. Milowsky, David M. Nanus, Neil H. Bander	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact